


NAVIGATING ADVANCEMENTS IN DIAGNOSIS & TREATMENT OF AXIAL SPONDYLOARTHRITIS

 ANNENBERG CENTER FOR HEALTH SCIENCES
AT EISENHOWER
Imparting knowledge. Improving patient care.

This activity is supported by an educational grant from Eli Lilly.



References

1. Furst DE, Louie JS. Targeting inflammatory pathways in axial spondyloarthritis. *Arthritis Res Ther*. 2019;21(1):135. doi:10.1186/s13075-019-1885-z.
2. Landewé R, van Tubergen A. Clinical Tools to Assess and Monitor Spondyloarthritis. *Curr Rheumatol Rep*. 2015;17(7):47. doi:10.1007/s11926-015-0522-3.
3. Robinson PC, Sengupta R, Siebert S. Non-Radiographic Axial Spondyloarthritis (nr-axSpA): Advances in Classification, Imaging and Therapy. *Rheumatol Ther*. 2019;6(2):165-177. doi:10.1007/s40744-019-0146-6.
4. Ghosh N, Ruderman EM. Nonradiographic axial spondyloarthritis: clinical and therapeutic relevance. *Arthritis Res Ther*. 2017;19(1):286. doi:10.1186/s13075-017-1493-8.
5. MD Magazine Staff. HCPLive.com. Spondyloarthritis: Educational Gaps and Unmet Needs. Posted May 24, 2016. Available at <https://www.mdmag.com/insights/spondyloarthritis/spondyloarthritis-educational-gaps-and-unmet-needs>. Accessed July 3, 2020.
6. Siebert S, Millar NL, McInnes IB. Why did IL-23p19 inhibition fail in AS: a tale of tissues, trials or translation? *Ann Rheum Dis*. 2019;78(8):1015-1018. doi:10.1136/annrheumdis-2018-213654
7. Elfein J. Back pain in the U.S.—Statistics & Facts. Statista.com. Published Nov 21, 2019. Available at <https://www.statista.com/topics/4333/back-pain-in-the-us>. Accessed July 6, 2020.
8. Shmagel A, Foley R, Ibrahim H. Epidemiology of Chronic Low Back Pain in US Adults: Data From the 2009-2010 National Health and Nutrition Examination Survey. *Arthritis Care Res (Hoboken)*. 2016;68(11):1688-1694. doi:10.1002/acr.22890.
9. Tsoi C, Griffith JF, Lee RKL, Wong PCH, Tam LS. Imaging of sacroiliitis: Current status, limitations and pitfalls. *Quant Imaging Med Surg*. 2019;9(2):318-335. doi:10.21037/qims.2018.11.10.
10. Rusman T, van Vollenhoven RF, van der Horst-Bruinsma IE. Gender Differences in Axial Spondyloarthritis: Women Are Not So Lucky. *Curr Rheumatol Rep*. 2018;20(6):35. Published 2018 May 12. doi:10.1007/s11926-018-0744-2.
11. Tournadre A, Pereira B, Lhoste A, et al. Differences between women and men with recent-onset axial spondyloarthritis: results from a prospective multicenter French cohort. *Arthritis Care Res (Hoboken)*. 2013;65(9):1482-1489. doi:10.1002/acr.22001.
12. Ward MM, Deodhar A, Akl EA, et al. American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network 2015 Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis. *Arthritis Rheumatol*. 2016; 68(2):282–298. doi:10.1002/art.39298.
13. Singh JA, Saag KG, Bridges SL Jr, et al. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. *Arthritis Rheumatol*. 2016;68(1):1-26. doi:10.1002/art.39480.
14. Yu DT, van Tubergen A. Diagnosis and differential diagnosis of axial spondyloarthritis (ankylosing spondylitis and nonradiographic axial spondyloarthritis) in adults. In: Sieper J, Romain PJ, ed. *UpToDate*. Waltham, Mass.: UpToDate, 2019.
15. Deodhar A, Gensler LS, Kay J, et al. A Fifty-Two-Week, Randomized, Placebo-Controlled Trial of Certolizumab Pegol in Nonradiographic Axial Spondyloarthritis. *Arthritis Rheumatol*. 2019;71(7):1101-1111. doi:10.1002/art.40866
16. Ward MM, Deodhar A, Gensler LS, et al. 2019 Update of the American College of Rheumatology/ Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis. *Arthritis Rheumatol*. 2019; 71(10):1599–1613. DOI 10.1002/art.41042.
17. Danve A, Reddy A, Vakil-Gilani K, et al. Routine Assessment of Patient Index Data 3 score (RAPID3) correlates well with Bath Ankylosing Spondylitis Disease Activity index (BASDAI) in the assessment of disease activity and

NAVIGATING ADVANCEMENTS IN DIAGNOSIS & TREATMENT OF AXIAL SPONDYLOARTHRITIS




 ANNENBERG CENTER FOR HEALTH SCIENCES
AT EISENHOWER
Imparting knowledge. Improving patient care.

This activity is supported by an educational grant from Eli Lilly.

- monitoring progression of axial spondyloarthritis. *Clinical Rheumatology*. 2015;34(1):117-124. DOI: 10.1007/s10067-014-2827-4.
18. Castrejón I, Pincus T, Wendling D, Dougados M. Responsiveness of a simple RAPID-3-like index compared to disease-specific BASDAI and ASDAS indices in patients with axial spondyloarthritis. *RMD Open*. 2016;2(2):e000235. Published 2016 Jul 7. doi:10.1136/rmdopen-2015-000235
 19. van der Heijde D, Ramiro S, Landewé R, et al. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. *Ann Rheum Dis*. 2017;76:978–991.
 20. Song IH, Poddubnyy DA, Rudwaleit M, Sieper J. Benefits and risks of ankylosing spondylitis treatment with nonsteroidal antiinflammatory drugs. *Arthritis Rheum*. 2008;58(4):929-938. doi:10.1002/art.23275
 21. Deodhar A, van der Heijde D, Gensler LS, et al. Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial. *Lancet*. 2020;395(10217):53-64. doi:10.1016/S0140-6736(19)32971-X.
 22. Baeten D, Sieper J, Braun J, et al. Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis. *N Engl J Med*. 2015;373:2534–2548.
 23. Braun J, Blanco R, Dokoupilova E, et al. Secukinumab 150 mg significantly improved signs and symptoms of non-radiographic axial spondyloarthritis: 52-week results from the phase III PREVENT study. Presented at: EULAR 2020; June 3-6, 2020; Abstract OP0106. https://ard.bmj.com/content/79/Suppl_1/69
 24. Joszt L. Secukinumab Approved to Treat Nonradiographic Axial Spondyloarthritis Based on Safety, Efficacy of PREVENT. Posted June 19, 2020. Available at <https://www.ajmc.com/newsroom/secukinumab-approved-to-treat-nonradiographic-axial-spondyloarthritis-based-on-safety-efficacy-of-prevent>. Accessed July 29, 2020.
 25. Tahir H. Therapies in ankylosing spondylitis—from clinical trials to clinical practice. *Rheumatology (Oxford)*. 2018;57(suppl_6):vi23-vi28. doi:10.1093/rheumatology/key152
 26. Baraliakos X, Borah B, Braun J, et al. Long-term effects of secukinumab on MRI findings in relation to clinical efficacy in subjects with active ankylosing spondylitis: an observational study. *Ann Rheum Dis*. 2016;75:408–412.
 27. Deodhar A, Mease PJ, McInnes IB, et al. Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data. *Arthritis Res Ther*. 2019;21(1):111. doi:10.1186/s13075-019-1882-2.
 28. Dubash S, Bridgwood C, McGonagle D, Marzo-Ortega H. The advent of IL-17A blockade in ankylosing spondylitis: secukinumab, ixekizumab and beyond. *Expert Rev Clin Immunol*. 2019;15(2):123-134. doi:10.1080/1744666X.2019.1561281.
 29. Adalimumab. Prescribing Information. Revised Jan 2008. Available at https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/125057s0110lbl.pdf
 30. Mounach A, El Maghraoui A. Efficacy and safety of adalimumab in ankylosing spondylitis. *Open Access Rheumatol*. 2014;6:83-90. doi:10.2147/OARRR.S44550.
 31. Etanercept. Highlights of prescribing information. Revised: 9/2017; Reference ID: 4155023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/103795s5556lbl.pdf
 32. Gorman JD, Sack KE, Davis JC Jr. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. *N Engl J Med*. 2002;346(18):1349-1356. doi:10.1056/NEJMoa012664
 33. CZP. Highlights of prescribing information. Reference ID: 4410921. Revised 03/2019. Available at https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/125160s237lbl.pdf
 34. Golimumab. Highlights of prescribing information. Reference ID: 4048329. Revised 01/2017. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125289s135lbl.pdf
 35. Infliximab. Revised: February 2011. https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/103772s5281lbl.pdf
 36. Kunzmann K. FDA Approves Ixekizumab for Non-Radiographic Axial Spondyloarthritis. Posted June 1, 2020. Available at <https://www.mdmag.com/medical-news/fda-ixekizumab-non-radiographic-axial-spondyloarthritis>. Accessed July 9, 2020.

NAVIGATING ADVANCEMENTS IN DIAGNOSIS & TREATMENT OF AXIAL SPONDYLOARTHRITIS



 ANNENBERG CENTER FOR HEALTH SCIENCES
AT EISENHOWER
Imparting knowledge. Improving patient care.

This activity is supported by an educational grant from Eli Lilly.

37. Pedersen SJ, Maksymowych WP. Beyond the TNF- α Inhibitors: New and Emerging Targeted Therapies for Patients with Axial Spondyloarthritis and their Relation to Pathophysiology. *Drugs*. 2018;78(14):1397–1418.
38. van der Heijde D, Gensler L, Deodhar A, et al. Dual Neutralization of IL-17A and IL-17F with Bimekizumab in Patients with Active Ankylosing Spondylitis: 48-Week Efficacy and Safety Results from a Phase 2b, Randomized, Blinded, Placebo-Controlled, Dose-Ranging Study [abstract]. *Arthritis Rheumatol*. 2019; 71 (suppl 10). <https://acrabstracts.org/abstract/dual-neutralization-of-il-17a-and-il-17f-with-bimekizumab-in-patients-with-active-ankylosing-spondylitis-48-week-efficacy-and-safety-results-from-a-phase-2b-randomized-blinded-placebo-controlled/>. Accessed July 5, 2020.
39. van der Heijde D, Baraliakos X, Gensler LS, et al. Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial. *Lancet*. 2018;392(10162):2378-2387. doi:10.1016/S0140-6736(18)32463-2
40. van der Heijde D, Deodhar A, Wei JC, et al. Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study. *Ann Rheum Dis*. 2017;76(8):1340-1347. doi:10.1136/annrheumdis-2016-210322.
41. Mease P. Emerging Immunomodulatory Therapies and New Treatment Paradigms for Axial Spondyloarthritis. *Curr Rheumatol Rep*. 2019;21(7):35.
42. Reis J, Vender R, Torres T. Bimekizumab: The First Dual Inhibitor of Interleukin (IL)-17A and IL-17F for the Treatment of Psoriatic Disease and Ankylosing Spondylitis. *BioDrugs*. 2019;33(4):391-399. doi:10.1007/s40259-019-00361-6.
43. van der Heijde D. Efficacy and safety of upadacitinib in a randomized, double-blind, placebo-controlled, multicenter phase 2/3 clinical study of patients with active ankylosing spondylitis. Presented at: American College of Rheumatology/Association of Rheumatology Professionals Annual Meeting; Nov. 9-13, 2019; Atlanta.
44. ClinicalTrials.gov. Treat to Target Trial in Axial Spondylo Arthritis: The TICOSPA (Tight Control in Spondyloarthritis) (TICOSPA). Last Update Posted: September 27, 2019. Available at <https://clinicaltrials.gov/ct2/show/NCT03043846>.
45. Sullivan G. Trials examine T2T strategy in axial spondyloarthritis. *RheumatologyNews*. MDedge.com. Posted October 25, 2019. Available at <https://www.mdedge.com/rheumatology/article/210872/spondyloarthropathies/trials-examine-t2t-strategy-axial>. Accessed July 6, 2020.
46. Spondylitis Association of America. Non-Medicinal Approaches To Treating Spondyloarthritis. Available at <https://spondylitis.org/spondylitis-plus/non-medicinal-approaches-to-treating-spondyloarthritis/>. Accessed July 6, 2020.